HRAS and ectomesenchymoma: In our clinical setting, TT with MEK-inhibitor cobimetinib in a patient with ectomesenchymoma-harboring HRAS p.R61Q genetic variant leading to RAS–RAF–MEK pathway activation was unsuccessful.